Vetter's Skokie site successfully manufactures batches on new clinical syringe filling line
Additional storage expansion strengthens the facilities’ ability to meet increased customer demand in prefilled syringes.
Vetter's new clinical syringe line has already manufactured for its customers a double digit number of batches for use in early clinical trials. The line is part of growth expansion activities that have been undertaken at its Skokie facility to help satisfy growing customer demand. It also includes an increase in storage that is designed to help manage the continued growth in syringe fills and overall larger batch sizes.
Since beginning full operations in late 2011, Vetter’s clinical manufacturing facility located at the Illinois Science + Technology Park in suburban Chicago has been expanding to meet growing customer demands. Recently, this included six new chest freezers, two upright freezers and two refrigerator units. As a result, storage will be expanded by the end of the year to increase capacity by 150%. Combined with the new syringe line, these activities will help manage the increase the CDMO is experiencing in syringe projects for early clinical stages and in overall larger batch sizes.
In addition to the many clinical batches filled for customers in vials – both for aseptic liquid and lyophilized products – the solution provider has successfully launched an aseptic syringe filling line. “Year to date, a double digit number of clinical batches have been manufactured for customers and we anticipate a significant increase in the number of batches in the coming years”, explains Dr. Susanne Resatz, President of Vetter Development Services USA. This reflects the trend the company sees through its continuous dialogue with new and existing customers, as starting syringe work in the early clinical phases can cut up to 18 months off time-to-market. “Given our experience at this facility with filling and lyophilization, many of our customers are returning for development work for a second, third, or even fourth molecule. As a result of this, our outlook for future performance is very positive as demonstrated by a solid pipeline filled with high quality customer projects for biologics,” Dr Resatz adds.
Vetter’s Skokie facility is the company’s US clinical manufacturing site, providing development support for preclinical through phase II injectables, primarily complex biologics. The facility, currently operating with a growing staff of more than 60, has solid experience with a variety of complex compounds, and has already made more than five transfers to the company’s European commercial facilities to prepare for commercial launch, with more to follow in the near future. The site offers all the resources needed for efficient early-stage clinical manufacturing, including chemical analysis and microbiology labs, material preparation and compounding functions. At the heart of the facility are its cleanrooms, followed by visual inspection capabilities and GMP storage. The facility has collaborated with (bio-)pharmaceutical companies from various continents including the US, Europe, Asia, and the Middle East.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance